Close

FDA approves Vertex Pharmaceuticals' Journavx tablets for acute pain treatment; new drug targets sodium channels in peripheral nervous system before pain signals reach brain

Jan 31, 2025 Press Release 1 min read

Exclusive Industry Insights

By submitting, you agree to our Privacy Policy

Share this article:

January 31, 2025 (press release) –

The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to severe acute pain in adults. The drug is manufactured by Vertex Pharmaceuticals. According to the FDA, Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system before pain signals reach the brain. 

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistribute or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

Stay Ahead of Changes

Don't Wait. Stay Informed.

The world and your industry are changing too fast. You need to know what's happening, and our Legislation Monitor can help. It's a critical resource for anyone who wants to stay ahead of regulatory and legal challenges. Then, discover the other ways that Industry Intelligence Inc. can help your business.

Cookie Preferences

This website uses cookies to enhance your browsing experience, analyze site performance, and deliver personalized content. We use a minimal cookie to remember your preferences. For detailed information about our cookie usage, please review our Privacy Policy.